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Abstract
Introduction—Heart failure (HF) and atrial fibrillation (AF) have been associated with a higher
risk of Alzheimer’s disease (AD). Whether HF and AF are related to AD by enhancing AD
neuropathological changes is unknown.
Methods—We applied network analyses and multiple logistic regression models to assess the
association between HF and AF with severity of AD neuropathology in patients from the National
Alzheimer’s Coordinating Center database with primary neuropathological diagnosis of AD.
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Results—We included 1593 patients, of whom 129 had HF and 250 had AF. HF and AF patients
were older and had milder AD pathology. In the network analyses, HF and AF were associated
with milder AD neuropathology. In the regression analyses, age (odds ratio [OR] 0.94, 95%
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confidence interval [CI] 0.93–0.95 per 1-year increase in age, P <.001) and the interaction term HF
× AF (OR 0.61, 95% CI 0.40–0.91, P = .014) were inversely related to severe AD pathology,
whereas APOE ε4 genotype showed a direct association (OR 1.68, 95% CI 1.31–2.16). Vascular
neuropathology was more frequent in patient with HF and AF patients than in those without.
Discussion—HF and AF had milder AD neuropathology. Patients with milder AD lived longer
and had more exposure to vascular risk factors. HF and AF patients showed a higher frequency of
vascular neuropathology, which could have contributed to lower the threshold for clinically
evident dementia.
Keywords
Atrial fibrillation; Heart failure; Dementia; Alzheimer’s disease; Vascular dementia;
Neuropathology
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1. Introduction
Heart failure (HF), atrial fibrillation (AF), and dementia are major health care challenges
that become more prevalent with age [1–3]. The number of people over 65 years will
increase from 420 million in 2000 to 1 billion by 2030 [4]. Therefore, this segment will
grow from 7% to 12% of the population [4]. In consequence, the number of individuals
living with dementia is predicted to escalate from 35.6 million in 2010, to 65.7 million in
2030, and 115.4 million in 2050 [1]. Similarly, the prevalence of AF in the US population is
expected to increase from 5.2 million in 2010 to 12.2 million in 2030 [2].
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HF and AF constitute promising targets for dementia prevention. Evidence suggests that HF
and AF are associated to a higher risk of cognitive impairment and dementia, irrespective of
stroke history [5,6]. Whereas data from population-based studies show that HF is associated
with a higher risk of Alzheimer’s disease (AD) [7,8], AF is not associated equally with all
types of dementias [6]. Although there is evidence supporting the association between AF
and dementia secondary to cerebrovascular disease, the relationship between AF and AD is
still controversial [6]. One study that examined neuropathological changes associated with
AF found that patients with permanent AF were 40%–50% more likely to have AD changes
than those without AF, but these associations were not statistically significant [9].
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Whether the higher AD risk of HF and AF is mediated through a greater burden of AD
pathological changes is unknown. Several possible mechanisms may enhance AD-related
pathological processes in HF and AF patients. Amyloid β clearance may be compromised in
HF patients, whereas stroke-free AF patients have reduced hippocampal volume compared
with matched subjects without AF, meaning that AF could be implicated in direct or indirect
neurodegenerative processes [10,11]. Also, AF-related brain infarcts may potentiate AD
pathological changes through secondary mechanisms [12].
In the present study, we aimed to investigate whether there is an association between HF and
AF with severe AD neuropathology among cases with primary diagnosis of AD from the
National Alzheimer’s Coordinating Center (NACC) database.
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2. Methods
The NACC was established by the National Institute on Aging in 1999 with the aim of
enabling collaborative research (U01 AG016976). The NACC collects data from 34 past and
present National Institute of Aging–funded Alzheimer’s disease Centers across the USA.
For this study, neuropathological data were collected from the NACC Neuropathology Data
Set, and clinical data from the same cases were obtained from the NACC Uniform Data Sets
[13–15]. The Uniform Data Set has gathered information about demographic data, clinical
manifestations, clinical diagnoses, neurological examination, functional status,
neuropsychological assessment, genetic data, and neuropathological diagnoses since 2005.
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For most of the neuropathological diagnoses, two categories were available: primary or
contributing. For the purpose of this study, we selected cases with primary AD diagnosis.
Cases received an AD neuropathological diagnosis based on Braak staging [16] and
Consortium to Establish a Registry for Alzheimer’s Disease scores for likelihood of AD [17]
if cases reached an intermediate probability. As such, the study cohort comprised patients
with primary neuropathological diagnosis of AD without contributing cerebrovascular
disease or with a degree of vascular neuropathology that did not reach the threshold for
mixed dementia. This was possible because NACC includes two categories for vascular
neuropathology (1) CVD (cerebrovascular disease), in which vascular neuropathology was
classified as a primary or contributing neuropathology (Items 20E1-20E2 in Neuropathology
Data Set) and (2) VP (vascular pathology) (Item 12), in which vascular neuropathology was
recorded but did not reach a threshold deemed sufficient to contribute to clinical status.
Cases in which AD was only contributing and not the primary neuropathological diagnosis
were excluded. We decided to restrict the study population to patients with primary AD
diagnosis because we wanted to test the hypothesis of whether HF and AF are implicated in
pathophysiological mechanisms of AD degeneration. This would have been impracticable if
we used a cohort comprising patients with mixed dementia in which secondary AD only
represented a contributing secondary pathological mechanism.
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We recorded data regarding sex, age at the onset of cognitive decline, age at the last visit,
age at death, years of education, history of hypertension, AF, diabetes mellitus,
hyperlipidemia, smoking (more than 100 cigarettes smoked in a lifetime), stroke, transient
ischemic attack (TIA), and HF. These variables were coded as absent, recent/active, or
remote/inactive. We merged active and inactive categories and compared them with the
“absent” category. For the purpose of this study, patients were considered to have AF and
HF based on their medical history (in any of all the available Uniform Data Set visits, form
A5). We defined four clinical phenotypes (CPs) according to the presence or absence of HF
and AF—(1) CP1: no HF and no AF, (2) CP2: AF without HF, (3) CP3: HF without AF, and
(4) CP4: HF and AF present. History of stroke was defined by the presence of an affirmative
response in any of the following three variables comprised in the original data set: stroke,
history of stroke, and temporal relationship between stroke and onset of cognitive
impairment.
We used Braak stages (extent of neurofibrillary tangles) to classify the severity of ADrelated neuropathological findings into severe (stages V/VI) and milder (stages III/IV) [16].
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Neuropathological vascular features comprised microinfarcts, lacunar macroscopic infarcts
(lacunes), and larger macroscopic infarcts. The criteria used by the neuropathologists to
assess the vascular features are described in the Neuropathology Diagnosis Coding
Guidebook (https://www.alz.washington.edu/NONMEMBER/NP/npguide9.pdf). We defined
four neuropathological profiles (NPs) on the basis of AD and vascular neuropathology—(1)
NP1: Braak III/IV + vascular neuropathology, (2) NP2: Braak III/IV without vascular
neuropathology, (3) NP3: Braak V/VI + vascular neuropathology, and (4) NP4: Braak V/VI
without vascular neuropathology.
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We used the NACC neuropsychological battery to assess cognitive status in the last visit
before death [15]. The battery comprised the following domains and tests—(1) general
cognitive impairment: Mini-Mental State Examination [18]; (2) executive functions: Digit
Span Backward (Wechsler Memory Scale—Revised) [19], Digit Symbol Coding (Wechsler
Adult Intelligence Scale—Revised) [20], and Trail Making Test, Part B [21]; (3) memory:
immediate and delayed recall (Story A, Wechsler Memory Scale—Revised) [19]; (4)
language: animal and vegetable list generation (verbal fluency) [22] and Boston Naming
Test (naming) [23]; (5) attention: Digit Span Forward (Wechsler Memory Scale—Revised)
[18] and Trail Making Test, Part A [20–24]. The dementia-related functional status was
assessed according to the Clinical Dementia Rating (CDR) sum of boxes [25].
2.1. Statistical analysis
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We performed univariate analyses to compare demographic characteristics, vascular risk
factors, vascular comorbidities, and neuropathological findings between patients with and
without AF and HF. The c2 to compare proportions and one-way analysis of variance to
compare means across the four CPs. All tests were two tailed, and a P value <.05 was
deemed statistically significant. We developed a forward step-by-step multiple logistic
regression model to test whether AF and HF were associated with severe AD pathology
(Braak stages V/VI). This model was adjusted for demographic data (e.g., age and sex), risk
factors (e.g., hypertension, hyperlipidemia, smoking, and diabetes mellitus), and history of
stroke/TIA. Measures of association were expressed as odds ratios (ORs) and 95%
confidence intervals (CIs). We estimated the proportion of severe AD pathological findings
(e.g., Braak stages V/VI), vascular neuropathology (e.g., microinfarcts, lacunes, or larger
infarcts), and the frequency or each of the four prespecified NPs based on AD findings and
vascular neuropathology across the four prespecified clinical HF/AF phenotypes. We used
IBM SPSS Statistics 20.0 for Macintosh (IBM Corp.) for all statistical analyses.
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As a post hoc analysis based on preliminary results of this study, we developed logistic
regression analyses to identify predictors of early death. For this purpose, we used the lowest
quintile of age at death (<72 years) as the dependent variable.
2.2. Network analysis
We built a network by relating demographic variables, risk factors, comorbidities, and
pathological findings. We divided the data set into training and validation sets. The links
between these variables, or nodes, were calculated by using relative risk as the correlation
measure. We retained only relative risks that where above a certain threshold, which was
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defined on the basis of the limit at which the giant component was first detected [26]. We
identified connections that were stronger among patients with HF and AF than among
patients without. We performed a modularity analysis based on the concept of topological
overlap (analysis of the structure of the density and pattern of connections of the nodes
within the network) to determine how variables were connected between each other [27]. For
the network analyses, we were unable to use continuous variables; thus, we dichotomized
age into <82 and 82 years on the basis of the median age of the cohort at death.

3. Results
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The study cohort comprised 1593 patients with primary diagnosis of AD (Fig. 1). A total of
129 patients had HF (8.1%) and 250 had AF (15.7%). Comparisons of demographic data,
vascular risk factors, comorbidities, clinical diagnoses, and neuropathological findings
across the four CPs are shown in Table 1. AD patients with HF and AF were older at the
time of onset of cognitive decline and at death, had less frequent severe AD changes on
neuropathological examination, and had more frequent noncontributory vascular
neuropathology than those without HF or AF. Clinically, patients with HF and AF were
more frequently considered as having normal cognition and were more often diagnosed as
having dementia because of cerebrovascular disease than those without. Hypertension and
all vascular comorbidities were more common in HF and AF patients than in those without.
In general, cognitive performance and overall functional status (CDR) were better in patients
with HF + AF than in those without (Table 2).
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In the logistic regression model for severe AD changes, age (OR 0.94, 95% CI 0.93–0.95 per
1-year increase in age, P < .001) and the interaction term HF × AF (OR 0.61, 95% CI 0.40–
0.91, P = .014) were inversely related to severe AD pathology, whereas APOE ε4 genotype
showed a direct association (OR 1.68, 95% CI 1.31–2.16). Adding the interaction term
APOE ε4 × HF × AF did not significantly affect these results.
We used a threshold of 1.20 for the network analyses (Fig. 1). The giant component
comprised all vascular findings on neuropathological examination. The modularity analysis
showed that the network had a high density of connections between HF, AF, vascular risk
factors, and stroke, which belonged to the same module. HF and AF were only connected
with milder AD neuropathological findings, and there was lack of connection with Braak
stages V/VI. Conversely, HF and AF were highly connected to vascular neuropathology.
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The frequency of severe AD pathology significantly decreased across clinical AF/HF
phenotypes CP1 to CP4 (Fig. 2, panel A). Likewise, there were increasing proportions of
vascular neuropathology across the same groups (Fig. 2, panel B). As shown in Fig. 3, the
NPs AF and HF showed less severe AD pathology and more vascular neuropathology; and
the combination of HF and AF had an additive effect resulting in even less frequent severe
AD changes and more frequent vascular neuropathology.
HF (OR 0.29, 95% CI 0.09–0.94), AF (OR 0.22, 95% CI 0.11–0.45), and Braak stages V/VI
(OR 3.07, 95% CI 1.87–5.04) were significantly associated with early death in the post hoc
logistic regression model (Fig. 2).
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4. Discussion
Evidence suggests that stroke risk factors such as midlife hypertension and obesity, diabetes,
smoking, and physical inactivity and comorbidities such as HF and AF are independently
associated with an increased risk of AD and vascular cognitive impairment [6–8,28].
Contrary to our hypothesis, in the present study of cases from the NACC database with
primary diagnosis of AD, we found that patients with HF and AF had less frequent severe
AD changes on neuropathological examination than those without.
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In the logistic regression models for severe AD pathology, the odds of showing severe AD
pathology decreased by 5% per 1-year increase in age at death and 39% for patients who had
both HF and AF. The network analyses showed an association between HF and AF with
milder AD neuropathology. Together, these findings suggest that HF and AF occur more
frequently in patients with milder AD pathology, who because of a more benign AD course
may present with cognitive decline at older ages, live longer, and are more exposed to
vascular risk factors leading to a higher prevalence of cardiovascular comorbidities [29].
This is further reinforced by the fact that severe AD pathology increased 3-fold the risk of
early death in the study cohort and also by the finding of younger age of onset of cognitive
decline among AD patients without HF or AF [2,30].
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Another potential explanation for our findings is that HF and AF precede dementia
symptoms and lead to overt dementia not by enhancing AD pathology, but rather by a higher
prevalence of vascular neuropathology. Subjects with milder AD pathology would be
clinically diagnosed with AD only in the presence of enough vascular neuropathology to
lower the threshold for cognitive impairment [31], As such, the higher frequency of AD
diagnosis among HF and AF patients found in prior studies may be explained by
symptomatic and asymptomatic brain infarcts uncovering mild forms of AD [5,6].
Interestingly, the severity of vascular neuropathology in this cohort was a priori regarded as
nonsignificant enough to clinically influence on cognitive performance by expert NACC
neuropathologists. Indeed, HF and AF showed an additive effect in the proportion of patients
with milder AD changes and greater vascular neuropathology. Also, AD patients with HF
and AF had slightly better age- and sex-adjusted cognitive performances and overall
functional status as those without, further supporting the idea that apparently nonclinically
relevant vascular neuropathology may have lowered the threshold for cognitive impairment
in older HF and AF patients who had milder AD neuropathology [31].
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Our findings suggest that the apparent association between HF and AF with higher risk of
AD is unlikely mediated through the enhancement of primary AD-related mechanisms. The
higher proportion of primary AD with apparently, but not so, noncontributing vascular
neuropathology among HF and AF patients and the additive effect of HF and AF on the
frequency of vascular neuropathology suggest that brain infarcts otherwise regarded as
nonclinically contributory to the diagnosis of dementia by expert pathologists could still play
a role in secondary pathophysiological AD processes. Indeed, brain infarcts can lead to
remote localized cortical thinning through degeneration of connecting fiber tracts, on top of
the primary structural brain damage produced by ischemia itself [32]. Experimental and
preliminary clinical data suggest that pre-existing amyloid may stimulate secondary cortical
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neurodegenerative processes after acute stroke [7]. Chronic stroke-related inflammation is
also involved in secondary neurodegenerative processes and seems to be independent of
prior amyloid deposition [12]. However, all these findings need to be further validated.
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This study has limitations. First, information about the presence of HF and AF was not
systematically investigated and came from the subjects’ medical history as recorded
retrospectively during their follow-up visits. This might have resulted in the underdiagnosis
of the both conditions. However, it also reflects how history of HF and AF is usually
investigated in routine clinical practice. Also, based on the large sample size, the finding of
less severe AD pathology in patients who had HF or AF seems unlikely to be because of
chance. This is further reinforced by the adjustment for significant confounders in the
logistic regression models. Second, the retrospective ascertainment of HF and AF hinders
the identification of the time sequence in the association between HF/AF and dementia.
Third, we did not have information regarding the localization of brain infarcts, which would
have likely enriched the analysis. Fourth, information about prescribed oral anticoagulants,
antiplatelet agents, and other drugs were not available in the NACC data set. This precluded
us from adjusting the regression models for drugs that have the potential to reduce the
incidence of dementia or to delay its diagnosis. Despite this, the role of antithrombotic
agents in dementia prevention is unknown. Fifth, our results are not generalizable to all
types of dementia. The study cohort was designed to test the study hypothesis among
patients with primary diagnosis of AD and not other dementias. Although this is a highly
selected population, it still constitutes the most frequent type of dementia, and the results of
this study are relevant to explain how HF and AF help to lower the threshold of cognitive
impairment in patients with mild AD neurodegenerative changes.
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Our study suggests that subjects with milder AD pathology live longer. Hence, they are
exposed to a greater burden of vascular risk factors and have higher odds of developing HF
and AF. As a result, rather than being considered as possible causes of AD, HF and AF may
be possibly regarded as markers of milder AD pathology, lowering the threshold for the
detection of cognitive impairment in subjects with milder AD pathology because of a higher
presence of vascular neuropathology. In other words, HF and AF seem to contribute to the
clinical expression of dementia in individuals with milder forms of AD, who would
otherwise be able to function within cognitively acceptable limits. Strategies implemented
during early adulthood to prevent HF and AF, and to effectively manage both conditions
early after their diagnoses, may help delay the clinical expression of dementia among
patients with milder forms of AD.
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RESEARCH IN CONTEXT
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1.

Systematic review: The authors reviewed the literature using traditional (e.g.,
PubMed and Scopus) sources. Relevant citations are cited throughout the text.
Evidence suggests that heart failure (HF) and atrial fibrillation (AF) are
associated with a higher risk of cognitive impairment and dementia, including
Alzheimer’s disease (AD), irrespective of stroke history. The mechanisms
behind these associations are still unknown.

2.

Interpretation: Our findings suggest that HF and HD may be markers of
milder AD pathology. Both HF and AF may contribute to a higher apparent
dementia incidence by making milder forms of otherwise sub-clinical AD
become clinically evident because of more frequent coexisting vascular
neuropathology.

3.

Future directions: Further studies should investigate the temporal association
between HF, AF, and AD and whether clinically overt AD can be delayed or
prevented by avoiding HF and AF and/or by optimizing their treatment.
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Fig. 1.
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Network analyses for neuropathological Alzheimer’s disease (AD) findings. Each variable is
shown in a circle (node). Risk factors are shown in dark green, heart failure (HF) and atrial
fibrillation (AF) in light green, stroke in black, vascular neuropathological findings in gray
(borders in dotted lines), and Braak stages in red. The lines between circles are present only
when the degree of association between the connected variables is higher than the
prespecified threshold of 1.2. HF and AF are connected with milder AD pathology (Braak
stages III/IV). They are also highly connected with age, diabetes, hypertension, stroke, and
vascular neuropathology.
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Frequency of severe Alzheimer’s disease (AD) pathological findings and vascular
neuropathology in patients with and without atrial fibrillation (AF) and heart failure (HF).
Panel A shows the proportion of severe AD pathological findings (e.g., Braak V/VI) on
neuropathological examination for patients (i) without AF or HF, (ii) with AF, (iii) with HF,
and (iv) with AF + HF. Panel B shows the proportion of vascular neuropathology for the
same groups. Circles represent the proportion with neuropathological findings, and vertical
lines account for the 95% confidence intervals.
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Fig. 3.

Frequency of neuropathological profiles (NPs) of Alzheimer’s disease (AD) and vascular
neuropathology in patients with and without atrial fibrillation (AF) and heart failure (HF).
The figure shows the proportion of four prespecified NPs of AD findings and vascular
neuropathology (e.g., Braak III/IV + vascular neuropathology, Braak III/IV without vascular
neuropathology, Braak V/VI + vascular neuropathology, and Braak V/VI without vascular
neuropathology) for patients (i) without AF or HF, (ii) with AF, (iii) with HF, and (iv) with
AF + HF. VNP: vascular neuropathology (e.g., larger infarcts, lacunes, or microinfarcts).
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15.1 ± 3.2

45.1 (559/1240)

Hyperlipidemia, % (n)

Smoking, % (n)

10.2 (130/1271)
11.0 (140/1271)

Prior stroke, % (n)
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6.0 (73/1226)

Probable or possible AD, % (n)

Mixed AD + cerebrovascular disease, % (n)

19.4 (246/1271)
72.9 (926/1271)

Primary AD and noncontributory vascular neuropathology

Braak stages V and VI, % (n)

8.4 (106/1265)
14.7 (187/1268)

Larger infarcts, % (n)

Lacunar infarcts, % (n)

Vascular findings

38.9 (491/1271)

Pure AD

Neuropathology

3.5 (45/1271)
80.8 (991/1226)

Normal cognition, % (n)

Clinical diagnoses

15.0 (190/1268)

Prior TIA, %(n)

0.0 (0/1271)

HF, % (n)

Coronary artery disease, % (n)

0.0 (0/1271)

Atrial fibrillation, % (n)

Comorbidities

9.7 (123/1269)
47.5 (596/1256)

Diabetes mellitus, % (n)

54.2 (689/1271)

Hypertension, % (n)

Vascular risk factors

54.4 (692/1271)

Years of education, % (n)

Male sex, % (n)

0.8 ± 1.1

79.2 ± 10.4

Age at death, mean ± SD (years)

Years between last assessment and death, mean ± SD

70.6 ± 11.1

Age of onset of cognitive decline, mean ± SD (years)

Demographics

No AF and no HF

16.6 (33/199)

13.1 (26/199)

66.3 (132/199)

25.6 (51/199)

32.7 (65/199)

12.4 (23/185)

82.2 (152/199)

7.0 (14/199)

18.6 (37/199)

14.1 (28/199)

25.1 (50/199)

0.0 (0/199)

100.0 (199/199)

46.4 (91/196)

50.8 (100/197)

14.6 (29/199)

61.1 (121/198)

59.3 (118/199)

15.2 ± 3.2

0.7 ± 1.1

84.4 ± 7.8

75.5 ± 8.7

AF and no HF

26.4 (19/72)

11.1 (8/72)

58.3 (42/72)

31.9 (23/72)

34.7 (25/72)

15.7 (11/70)

80.0 (56/70)

2.8 (2/72)

22.2 (16/72)

13.9 (10/72)

41.7 (30/72)

100.0 (72/72)

0.0 (0/72)

59.4 (24/49)

50.7 (36/71)

8.3 (6/72)

76.4 (55/72)

54.2 (39/72)

14.1 ± 3.4

0.5 ± 0.8

86.5 ± 7.6

77.8 ± 9.8

HF and no AF

27.7 (14/51)

19.6 (10/51)

41.2 (21/51)

39.2 (20/51)

31.4 (16/51)

19.6 (9/46)

73.9 (34/46)

9.8 (5/51)

25.5 (13/51)

19.6 (10/51)

32.0 (16/50)

100.0 (51/51)

100.0 (51/51)

49.0 (24/49)

54.0 (27/50)

9.8 (5/51)

82.4 (42/51)

47.1 (24/51)

14.6 ± 4.0

0.6 ± 1.0

88.9 ± 7.2

83.4 ± 8.8

AF and HF

.001

.002

<.001

<.001

.08

<.001

.46

.026

<.001

.011

<.001

<.001

<.001

.09

.22

.55

<.001

.79

.19

.029

<.001

<.001

P value

Comparison of demographic data, vascular risk factors, and comorbidities between AD patients with and without AF and AD
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29.8 (378/1268)

36.2 (72/199)

20.6 (41/199)
45.8 (33/72)

20.8 (15/72)
51.0 (26/51)

29.4 (15/51)

AF and HF

<.001

.022

P value

NOTE. Clinical diagnoses may overlap (addition of the frequency of different diagnoses does not equal 100%), thus the sum of proportions is higher than 100%. Other diagnoses include Lewy body
dementia, corticobasal degeneration, frontotemporal dementia, and progressive supranuclear palsy.

Abbreviations: AD, Alzheimer’s disease; AF, atrial fibrillation; HF, heart failure; SD, standard deviation; TIA, transient ischemic attack.

17.4 (221/1268)

Either larger infarcts, lacunes or microinfarcts, % (n)
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Microinfarcts, % (n)

HF and no AF
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AF and no HF
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No AF and no HF
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−1.3 ± 1.2
−2.6 ± 2.0

Trail Making Test B, mean ± SD, Z score

−1.9 ± 1.2

Delayed memory, mean ± SD, Z score

−2.1 ± 1.2
−1.4 ± 1.2

Animal list, mean ± SD, Z score

Vegetable list, mean ± SD, Z score

11.5 ± 6.2

−3.9 ± 3.1

−1.0 ± 1.4

−1.3 ± 1.2

−1.8 ± 1.2

−3.3 ± 2.7

−1.9 ± 1.3

−2.2 ± 1.4

−2.8 ± 1.9

−1.2 ± 1.2

−1.7 ± 1.5

−10.7 ± 7.4

AF and no HF

10.8 ± 6.1

−4.0 ± 3.0

−0.9 ± 1.3

−1.2 ± 1.1

−1.8 ± 1.2

−2.4 ± 2.7

−1.8 ± 1.1

−1.9 ± 1.4

−3.2 ± 1.6

−1.0 ± 1.2

−1.9 ± 1.2

−9.8 ± 6.6

HF and no AF

7.7 ± 6.3

−3.4 ± 2.8

−0.6 ± 1.4

−0.7 ± 1.3

−1.5 ± 1.1

−2.6 ± 2.4

−1.2 ± 1.2

−1.4 ± 1.2

−2.3 ± 1.6

−0.8 ± 1.1

−1.4 ± 1.4

−7.2 ± 6.6

AF and HF

Abbreviations: AD, Alzheimer’s disease; AF, atrial fibrillation; CDR, clinical dementia rating; HF, heart failure; SD, standard deviation.

11.8 ± 6.0

−4.0 ± 3.0

Trail Making Test A, mean ± SD, Z score

CDR sum of boxes, mean ± SD

−1.3 ± 1.5

Digit Span Forward (Trials), mean ± SD, Z score

Attention

−3.5 ± 3.0

Boston, mean ± SD, Z score

Language (verbal fluency and naming)

−2.1 ± 1.3

Immediate memory, mean ± SD, Z score

Memory

−1.8 ± 1.6

Digit Span Backward (Trials), mean ± SD, Z score

−11.3 ± 7.6

Digit Symbol Coding, mean ± SD, Z score

Executive functions

Mini-Mental State Examination, mean ± SD, Z score

General cognitive function

Neuropsychological performance

No AF and no HF

<.001

.85

.012

.008

.002

.13

.015

.022

.52

.06

.68

.012

P value

Comparison of neuropsychological performance and functional status of AD patients with and without AF
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